Topelia's antiviral therapeutics for coronavirus infections advanced from concept to Phase 3 in just three years, showcasing our bold innovation

Learn More

Covid-19 The Ongoing Health Risk

While most patients diagnosed with COVID-19 develop only mild to moderate disease, approximately 20% will progress to severe/critical disease state requiring medical intervention and mechanical ventilation with poor prognosis for disease resolution in severe or critical cases. These sorts of outcomes are particularly seen in the elderly and those with co-morbidities¹.

Learn More

Latest News

Why Invest?

Topelia is developing and commercialising its proprietary TPL101 Antiviral Triple Therapy (ATT) for coronavirus infection.

Therapeutics: Our partnerships and collaborations

Topelia has established strong partnerships with world-renowned experts who bring specialised knowledge and robust resources. These collaborations will play a crucial role in guiding the development of Topelia's proprietary TPL101 Antiviral Triple Therapy (ATT) for treating coronavirus infections.

Our Pipeline

Topelia is committed to advancing the development of TPL101 to fight COVID-19 infections.

With its mechanism of action targeting conserved viral proteins, TPL101 has the potential to be an adaptable treatment. Its broad-spectrum antiviral properties suggest it may be effective not only for respiratory infections like coronaviruses and influenza (including Avian Influenza) but also for other viruses from the Flaviviridae family, such as Dengue, Zika, and Yellow Fever. This makes TPL101 a promising candidate in the battle against various viral infections.

Learn More